<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02995772</url>
  </required_header>
  <id_info>
    <org_study_id>049/PEP/08/2011</org_study_id>
    <nct_id>NCT02995772</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients</brief_title>
  <official_title>Preoperative Neoadjuvant Hormonal Therapy and Neoadjuvant Chemotherapy for Stage IIIB and IV Breast Cancer Patients in Dharmais National Cancer Center Hospital, Indonesia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dharmais National Cancer Center Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dharmais National Cancer Center Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study compared long term outcome of stage IIIB/C and IV breast cancer patients treated
      with neoadjuvant hormonal therapy (NAHT) and those treated with neoadjuvant chemotherapy
      (NACT)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study compared long term outcome of stage IIIB/C and IV breast cancer patients treated
      with neoadjuvant hormonal therapy (NAHT) and those treated with neoadjuvant chemotherapy
      (NACT) between 2011 and 2016.

      The primary end points are overall survival (OS) and progression free survival (PFS) with
      Kaplan Meier.

      This study was approved by Ethical Committee in Dharmais National Cancer Hospital.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>until minimum sample sizes are met</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progressive free survival</measure>
    <time_frame>until minimum sample sizes are met</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">107</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant hormonal therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neoadjuvant hormonal therapy: Aromatase inhibitors (Arimidex, Femara, Aromasin), Tamoxifen, SOB and AI, SOB and Tamoxifen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neoadjuvant chemotherapy: FAC 6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aromatase Inhibitors (Arimidex)</intervention_name>
    <description>Comparison of efficacy with chemotherapy</description>
    <arm_group_label>Neoadjuvant hormonal therapy</arm_group_label>
    <other_name>Anastrozole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>Comparison of efficacy with chemotherapy</description>
    <arm_group_label>Neoadjuvant hormonal therapy</arm_group_label>
    <other_name>Nolvadex</other_name>
    <other_name>Soltamox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SOB</intervention_name>
    <description>Comparison of efficacy with chemotherapy</description>
    <arm_group_label>Neoadjuvant hormonal therapy</arm_group_label>
    <other_name>Salpingo-oophorectomy Bilateral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FAC</intervention_name>
    <description>Comparison of efficacy with hormonal therapy</description>
    <arm_group_label>Neoadjuvant chemotherapy</arm_group_label>
    <other_name>Fluorouracil, Adriamycin, Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aromatase Inhibitors (Femara)</intervention_name>
    <description>Comparison of efficacy with chemotherapy</description>
    <arm_group_label>Neoadjuvant hormonal therapy</arm_group_label>
    <other_name>Letrozole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aromatase Inhibitors (Aromasin)</intervention_name>
    <description>Comparison of efficacy with chemotherapy</description>
    <arm_group_label>Neoadjuvant hormonal therapy</arm_group_label>
    <other_name>Exemestane</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  IIIB/C and IV stage of breast cancer

          -  received neoadjuvant hormonal therapy or neoadjuvant chemotherapy

          -  had first and second biopsy (surgery) within 6 months

        Exclusion Criteria:

          -  had mastectomy before treatment

          -  pregnant

          -  disagree to enter the study

          -  had been given hormonal therapy or chemotherapy before study

          -  had contra-indication of SOB for pre-menopausal patients
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramadhan Karsono, Doctoral</last_name>
    <role>Study Chair</role>
    <affiliation>Dharmais National Cancer Center Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ramadhan Ramli, PhD</last_name>
    <phone>+62-812-1045-970</phone>
    <email>ramadhan@dharmais-surgonc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dharmais National Cancer Center Hospital</name>
      <address>
        <city>Jakarta</city>
        <zip>11420</zip>
        <country>Indonesia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramadhan Ramli, PhD</last_name>
      <phone>+62-812-1045-970</phone>
      <email>ramadhan@dharmais-surgonc.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <results_reference>
    <citation>Semiglazov VF, Semiglazov VV, Dashyan GA, Ziltsova EK, Ivanov VG, Bozhok AA, Melnikova OA, Paltuev RM, Kletzel A, Berstein LM. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer. 2007 Jul 15;110(2):244-54.</citation>
    <PMID>17538978</PMID>
  </results_reference>
  <results_reference>
    <citation>Colleoni M, Montagna E. Neoadjuvant therapy for ER-positive breast cancers. Ann Oncol. 2012 Sep;23 Suppl 10:x243-8.</citation>
    <PMID>22987970</PMID>
  </results_reference>
  <results_reference>
    <citation>Chia YH, Ellis MJ, Ma CX. Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool. Br J Cancer. 2010 Sep 7;103(6):759-64. doi: 10.1038/sj.bjc.6605845. Epub 2010 Aug 10. Review.</citation>
    <PMID>20700118</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2016</study_first_submitted>
  <study_first_submitted_qc>December 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2016</study_first_posted>
  <last_update_submitted>January 17, 2018</last_update_submitted>
  <last_update_submitted_qc>January 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Anastrozole</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Exemestane</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>We have not decided on this yet</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

